Esperion Therapeutics Inc. [ESPR] fell -61.46% so far this year. What now?



Esperion Therapeutics Inc. [NASDAQ: ESPR] surged by $2.9 during the normal trading session on Tuesday and reaching a high of $10.02 during the day while it closed the day at $10.02. The company report on November 12, 2021 that Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021.

– Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients -.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


– In patients with metabolic syndrome NEXLETOL lowered hemoglobin A1c (HbA1c), fasting plasma glucose and low-density lipoprotein cholesterol (LDL-C), at week 12 -.

Esperion Therapeutics Inc. stock has also gained 17.74% of its value over the past 7 days. However, ESPR stock has declined by -26.59% in the 3 months of the year. Over the past six months meanwhile, it has lost -49.82% and lost -61.46% year-on date.

The market cap for ESPR stock reached $301.10 million, with 26.45 million shares outstanding and 26.26 million shares in the current float. Compared to the average trading volume of 1.02M shares, ESPR reached a trading volume of 4942936 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $15.91 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 19, 2021. While these analysts kept the previous recommendation, Morgan Stanley dropped their target price from $17 to $11. The new note on the price target was released on October 14, 2021, representing the official price target for Esperion Therapeutics Inc. stock. Previously, the target price had yet another drop from $37 to $20, while Stifel kept a Hold rating on ESPR stock.

The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.81, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 4.14.

ESPR stock trade performance evaluation

Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.74. With this latest performance, ESPR shares gained by 28.63% in over the last four-week period, additionally sinking by -49.82% over the last 6 months – not to mention a drop of -63.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 56.09, with the RSI for the last a single of trading hit 62.28, and the three-weeks RSI is set at 51.76 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 10.10, while it was recorded at 8.02 for the last single week of trading, and 19.10 for the last 200 days.

Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -53.35 and a Gross Margin at +98.71. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -63.09.

Return on Total Capital for ESPR is now -57.82, given the latest momentum, and Return on Invested Capital for the company is -70.67. Additionally, ESPR Total Debt to Total Capital is recorded at 136.16, with Total Debt to Total Assets ending up at 102.48.

Reflecting on the efficiency of the workforce at the company, Esperion Therapeutics Inc. [ESPR] managed to generate an average of -$299,689 per employee.Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.20.

Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock

With the latest financial reports released by the company, Esperion Therapeutics Inc. posted -3.89/share EPS, while the average EPS was predicted by analysts to be reported at -3.76/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Esperion Therapeutics Inc. [ESPR]: Insider Ownership positions

There are presently around $250 million, or 90.00% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: BELLEVUE GROUP AG with ownership of 4,519,164, which is approximately 0% of the company’s market cap and around 16.80% of the total institutional ownership; WASATCH ADVISORS INC, holding 3,274,360 shares of the stock with an approximate value of $32.81 million in ESPR stocks shares; and MEDITOR GROUP LTD, currently with $28.25 million in ESPR stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Esperion Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 58 institutional holders increased their position in Esperion Therapeutics Inc. [NASDAQ:ESPR] by around 2,754,752 shares. Additionally, 64 investors decreased positions by around 6,318,564 shares, while 40 investors held positions by with 15,919,460 shares. The mentioned changes placed institutional holdings at 24,992,776 shares, according to the latest SEC report filing. ESPR stock had 23 new institutional investments in for a total of 1,138,620 shares, while 24 institutional investors sold positions of 1,975,375 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam